Related Experiment Videos
Prospects for drug therapy for hyperlipoproteinaemia
1Institut de Recherches, Cliniques de Montréal, QC, Canada.
Diabete & Metabolisme
|April 1, 1995
Summary
New therapies for hyperlipoproteinaemia focus on improving existing molecules and developing novel drugs. Advances include potent cholesterol-lowering agents like atorvastatin and selective thyromimetics, alongside innovative approaches for future treatment.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
- Biochemistry
Background:
- Hyperlipoproteinaemia management relies on improving existing lipid-modulating agents.
- Novel therapeutic targets within the plasma lipid transport system are being explored.
- Understanding dyslipoproteinaemia pathophysiology drives drug discovery.
Purpose of the Study:
- To review recent advances in therapeutic strategies for hyperlipoproteinaemia.
- To highlight novel drug candidates targeting different aspects of lipid metabolism.
- To discuss future directions in drug development for lipid disorders.
Main Methods:
- Review of preclinical and clinical data on novel lipid-lowering agents.
- Analysis of mechanisms of action for inhibitors of HMG CoA reductase, ACAT, and cholesterol absorption.
- Exploration of emerging therapeutic modalities like gene therapy and cholesterol vaccination.
Main Results:
- Atorvastatin demonstrates potent LDL-cholesterol reduction and HDL-cholesterol increase.
- Selective thyromimetic CGS 26214 shows cholesterol-lowering activity and Lp(a) reduction.
- ACAT inhibitors and cholesterol absorption inhibitors (e.g., ACA-147, Sch48461) exhibit multi-faceted benefits, including antiatherogenic effects.
Conclusions:
- Therapeutic prospects for hyperlipoproteinaemia involve both enhancing known molecules and developing new ones.
- Emerging drugs offer improved potency and novel mechanisms for managing lipid disorders.
- Future treatments may focus on personalized approaches targeting specific disease causes.